Agios Pharmaceuticals, Inc. AGIO
31.76 USD -1.06 (-3.23%)
At closeNov 12, 2026, 4:01 PM EST
31.76 0.00 0.00%
After hours · Nov 12, 4:01 PM ET
31.56 Day range 32.63
22.34 52-week range 45.49
- YTD
- +16.68%
- 1 year
- -27.21%
News
seekingalpha.com Agios Pharmaceuticals, Inc. (AGIO) Q3 2026 Earnings Call Transcript Agios Pharmaceuticals, Inc. ( AGIO ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Morgan Sanford - Vice President of Investor Relations Brian Goff - CEO & Director Cecilia…
benzinga.com Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $35 Truist Securities analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $37 to $35.
benzinga.com HC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $62 HC Wainwright & Co. analyst Douglas Tsao maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $55 to $62.
marketbeat.com What Agios Pharmaceuticals (AGIO) Said on Its Q3 Earnings Call Agios Pharmaceuticals NASDAQ: AGIO reported record third-quarter product revenue as its thalassemia drug AQVESME continued its U.S. launch, while the company prepares for a delayed regulatory…
zacks.com Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Beats Revenue Estimates Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.09 per share versus the Zacks Consensus Estimate of a loss of $1.32. This compares to a loss of $1.78 per share a year ago.
benzinga.com Agios Pharmaceuticals Q3 2026 Earnings Call Transcript Agios Pharmaceuticals (NASDAQ:AGIO) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com Agios Pharmaceuticals Q3 EPS $(1.09) Beats $(1.20) Estimate, Sales $55.385M Beat $53.208M Estimate Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.09) per share which beat the analyst consensus estimate of $(1.20) by 9.17 percent. This is a 38.76 percent increase over losses…
globenewswire.com Agios Reports Third Quarter 2026 Financial Results and Provides Business Update Mitapivat (PYRUKYND® and AQVESME®) delivered worldwide net revenues of $55.4 million in third quarter of 2026, more than four times the $12.9 million reported in third quarter of 2025 Strong U.S.…
globenewswire.com Agios to Highlight Strength and Differentiation of Rare Hematology Portfolio with New Clinical Data for Mitapivat in Sickle Cell Disease and AG-236 in Polycythemia Vera at ASH 2026 Agios announces new clinical data across company's rare hematology portfolio that will be featured in oral and poster presentations during ASH 2026.
seekingalpha.com Agios: News On Sickle Cell Approval Decision Delay May Not Derail Bull Thesis (Upgrade) Agios Pharmaceuticals stock fell >15% after the FDA extended the mitapivat sNDA PDUFA date for sickle cell disease to February 2027. Mitapivat's efficacy in SCD is mixed—endpoint for pain crises not…- benzinga.com Agios Pharmaceuticals Says FDA Extends Mitapivat PDUFA Date For Sickle Cell Disease To February 1, 2027 FDA recently requested additional information to evaluate whether a REMS is necessary for mitapivat in sickle cell diseaseFDA classified Agios’ response to the information request as a major…
globenewswire.com Agios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDA FDA recently requested additional information to evaluate whether a REMS is necessary for mitapivat in sickle cell disease FDA classified Agios' response to the information request as a major…
zacks.com Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
benzinga.com HC Wainwright & Co. Assumes Agios Pharmaceuticals at Buy, Announces Price Target of $55 HC Wainwright & Co. analyst Douglas Tsao assumes Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy rating and announces Price Target of $55.
globenewswire.com Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET CAMBRIDGE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients…
benzinga.com Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $37 Truist Securities analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $39 to $37.
zacks.com AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know Agios faces a narrower growth path as tebapivat setbacks shift focus to mitapivat sales, SCD expansion and regulatory prospects.
zacks.com Agios' Growth Story Hinges on Mitapivat's Commercial Expansion AGIO's mitapivat is driving growth as Aqvesme gains traction, while an SCD opportunity and pipeline setbacks increase its importance.
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com B of A Securities Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $50 B of A Securities analyst Alec Stranahan maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $46 to $50.
benzinga.com Limoneira Posts Downbeat Q3 Results, Joins Cooper Companies, Navan And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session U.S. futures rose, while Limoneira fell 8.4% after missing earnings and sales estimates. Resolution Minerals and Cooper led other premarket decliners.
defenseworld.net Bank of New York Mellon Corp Invests $7.37 Million in Agios Pharmaceuticals, Inc. $AGIO Bank of New York Mellon Corp purchased a new position in Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) during the second quarter, according to the company in its most recent 13F filing with the…
seekingalpha.com Agios Pharmaceuticals: Indication Stacking Is Creating A Commercial Flywheel Agios is leveraging mitapivat's commercial platform across PK deficiency, thalassemia, and potentially sickle cell disease to build a durable rare-disease franchise. Thalassemia launch drove Q2 2026…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. ("Agios" or the "Company") (NASDAQ: AGIO). Such investors are…
defenseworld.net Assenagon Asset Management S.A. Has $3.86 Million Stock Holdings in Agios Pharmaceuticals, Inc. $AGIO Assenagon Asset Management S.A. lifted its stake in Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) by 54.8% during the second quarter, according to the company in its most recent Form 13F filing with the…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. (“Agios” or the “Company”) (NASDAQ: AGIO). Such investors are…
benzinga.com JP Morgan Maintains Neutral on Agios Pharmaceuticals, Raises Price Target to $34 JP Morgan analyst Tessa Romero maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and raises the price target from $31 to $34.
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. ("Agios" or the "Company") (NASDAQ: AGIO). Such investors are…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. (“Agios” or the “Company”) (NASDAQ: AGIO). Such investors are…
defenseworld.net Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Given Consensus Recommendation of “Hold” by Brokerages Agios Pharmaceuticals, Inc. (NASDAQ: AGIO - Get Free Report) has been assigned a consensus rating of "Hold" from the ten research firms that are covering the firm, MarketBeat Ratings reports. One…- benzinga.com Citigroup Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $52 Citigroup analyst Samantha Semenkow maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $46 to $52.
zacks.com AGIO Q2 Earnings Beat Estimates, Revenues Increase Year Over Year Agios tops Q2 revenue and earnings estimates as Aqvesme's launch and Pyrukynd sales fuel growth, while advancing its hematology pipeline.- benzinga.com Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $39 Truist Securities analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $41 to $39.
- benzinga.com HC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $55 HC Wainwright & Co. analyst Emily Bodnar maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $52 to $55.
benzinga.com Agios Pharmaceuticals Q2 EPS $(1.69) Misses $(1.67) Estimate, Sales $44.745M Beat $25.521M Estimate Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.69) per share which missed the analyst consensus estimate of $(1.67) by 1.2 percent. This is a 12.44 percent increase over losses…
benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Agios Reports Neutral Sickle Cell Data, Decides To Stop Development Agios Pharmaceuticals stops tebapivat development in sickle cell disease after Phase 2 study fails to prove meaningful differentiation.
benzinga.com HC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $52 HC Wainwright & Co. analyst Emily Bodnar maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $54 to $52.
benzinga.com Danaher Posts Q2 Results, Joins Calix, Equifax And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session US stock futures up, Nasdaq 100 gains 1%. Danaher Corp (DHR) shares fall 10.1% in pre-market trading. Other stocks also decline.- benzinga.com Agios Pharma Announces Topline Results From Phase 2 Trial Of Tebapivat, Oral Pyruvate Kinase Activator, In Patients Aged 16 Years Or Older With Sickle Cell Disease Hemoglobin response rates for tebapivat, a PK activator, were consistent with the class of medicine, but Phase 2 results did not establish a differentiated profile to support continued development in…
benzinga.com Why Is Agios Pharma Stock Soaring Tuesday? Agios Pharma (AGIO) stock spikes 15% as FDA grants Priority Review for sickle cell disease drug mitapivat. Details here.- benzinga.com RBC Capital Maintains Sector Perform on Agios Pharmaceuticals, Raises Price Target to $32 RBC Capital analyst Luca Issi maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Sector Perform and raises the price target from $28 to $32.
benzinga.com DigitalOcean, Agios Pharmaceuticals, Kingsoft Cloud And Other Big Stocks Moving Higher On Tuesday US stocks were mixed, Nasdaq fell 1%. DigitalOcean shares rose after strong revenue growth and earnings guidance. Other big gainers include CRNX, MAAS, and AGIO.- benzinga.com Truist Securities Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $41 Truist Securities analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $36 to $41.
- benzinga.com Agios Pharma Says FDA Accepts sNDA For Mitapivat In Sickle Cell Disease With Priority Review; PDUFA Goal Date November 1 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the U.S. Food…
- benzinga.com B of A Securities Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $46 B of A Securities analyst Alec Stranahan maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $40 to $46.
- benzinga.com Reported Saturday, Agios Presents RISE UP Phase 3 Data At EHA 2026 Showing Mitapivat Achieves 40.6% Hemoglobin Response Rate And 41.1% Reduction In Transfusion Burden Versus Placebo In Sickle Cell Disease Mitapivat demonstrated statistically significant improvement in hemoglobin response compared with placebo, with rapid onset and durable effectsNew analyses showed patients in mitapivat arm had…
- benzinga.com JP Morgan Maintains Neutral on Agios Pharmaceuticals, Lowers Price Target to $31 JP Morgan analyst Tessa Romero maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and lowers the price target from $36 to $31.
- benzinga.com Agios Acquires Global Rights to Experimental Blood Disorder Drug From South Korea's Oscotec Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced an agreement with…
- benzinga.com B of A Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $40 B of A Securities analyst Greg Harrison maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $41 to $40.